Introduction
Quantum BioPharma Ltd. (NASDAQ: QNTM) is a Canadian biopharmaceutical company focused on innovative treatments for challenging disorders, notably multiple sclerosis (MS). The company—formerly known as FSD Pharma—recently announced the completion of 180-day toxicology studies for its lead drug candidate Lucid-21-302 (“Lucid-MS”), marking a major milestone toward initiating Phase 2 trials ([1]). Lucid-MS is a patented new chemical entity that in preclinical models showed potential to remyelinate damaged nerves, addressing the underlying cause of MS ([2]). With no cure for MS today and a global MS treatment market of ~$23 billion ([2]), Quantum’s progress has drawn investor attention. This report examines Quantum’s fundamentals – dividend policy, leverage, liquidity, valuation, and key risks – in light of the Lucid-MS milestone and the company’s broader strategy.
Dividend Policy & History
No Regular Dividends: Quantum BioPharma does not pay a recurring dividend, as it devotes its resources to R&D and growth. The company explicitly states it has “no current intention to declare dividends… in the foreseeable future” ([3]). In fact, since going public in 2018, Quantum (formerly FSD Pharma) has never paid a cash dividend to shareholders ([4]). Management expects to reinvest any future earnings into product development and even alternative assets like Bitcoin, rather than distribute cash ([3]). Thus, QNTM’s dividend yield stands at 0%, reflecting its developmental-stage status.
Special Distributions: Instead of regular dividends, Quantum has occasionally rewarded shareholders through special distributions. In late 2023, it spun off its nutraceutical division Celly Nutrition (now Unbuzzd Wellness Inc.) by distributing shares of the new entity to FSD Pharma shareholders as a one-time stock dividend ([3]). More recently, the company outlined plans for a unique contingent value rights (CVR) dividend. In June 2025, Quantum announced its intention to issue CVRs on a 1:1 basis to shareholders, entitling them to a portion of any net proceeds from the company’s pending litigation against several banks ([5]) ([5]). Each CVR could pay 10%–50% of Quantum’s eventual recovery (if any) from the lawsuit, which seeks over $700 million in damages for alleged stock manipulation ([5]). As of October 2025, the record date for this special CVR dividend was reaffirmed for October 27, 2025 ([6]). These moves underscore that **shareholder returns, if any, will be highly event-specific – tied to spin-offs or legal outcomes – rather than recurring income streams. Investors in QNTM should therefore not expect traditional dividend income, but rather view the stock as a pure growth and capital appreciation play.
Leverage and Debt Maturities
Minimal Debt Load: Quantum BioPharma has maintained a light debt profile, especially after recent balance sheet improvements. By Q3 2025, the company had eliminated all outstanding convertible debentures, which were previously a major source of leverage ([7]). In the third quarter of 2025 alone, Quantum reduced total liabilities by 50%, from US$13.2 million down to US$6.6 million ([7]). This was primarily achieved by converting or settling the convertible debt and associated warrants entirely ([7]) ([7]). The result was a sharp improvement in capital structure: debt-to-equity dropped from 6.47× to 0.89× in one quarter ([7]), reflecting a shift to a nearly debt-free balance sheet.
Limited-Time: Join the Fraternity
No Significant Long-Term Loans:** Beyond those now-extinguished debentures, Quantum does not carry substantial long-term loans or bonds. In its latest annual filing, the company’s Capitalization and Indebtedness section was listed as “Not applicable” ([3]), signaling an absence of material interest-bearing debt. Management has proactively settled legacy obligations to preserve cash – for example, in late 2024 Quantum paid down and equity-settled over C$0.7 million of payables and debts ([3]) ([3]). By year-end 2024, only about C$0.8 million of debt remained on the books ([3]), which has since been further reduced. The company’s debts also carry fixed interest rates, avoiding exposure to rising rate risk ([3]). Overall, Quantum’s leverage is very low for a public company, which reduces bankruptcy risk and interest expense but also reflects its reliance on equity financing.
Financial Flexibility: To finance ongoing R&D, Quantum leans on equity raises instead of debt. It established an at-the-market (ATM) offering program in 2024 allowing sales of up to US$21.2 million in new shares via H.C. Wainwright ([8]). This provides flexibility to tap capital markets as needed. Additionally, the company occasionally uses creative financing: it once even loaned excess cash to its own CEO as a secured mortgage investment (earning 6–7% interest) – a related-party transaction that was fully repaid by 2025 ([3]) ([3]). Such maneuvers, while unconventional, highlight management’s willingness to utilize alternative funding arrangements. Going forward, Quantum’s lack of long-term debt means no major maturities coming due; the primary funding constraints will be its ability to issue equity or other instruments to fund costly clinical trials.
Liquidity and Coverage
Strong Cash Runway: Quantum BioPharma’s liquidity position has been bolstered alongside its debt cleanup. Management affirms that the company has sufficient cash on hand to fund operations beyond March 2027, with no “going concern” issues expected in the near term ([7]) ([7]). In the Q3 2025 update, the CFO stated Quantum now has enough cash to maintain basic operations into early 2027 ([7]). This confidence stems from a combination of cash reserves, reduced cash burn, and non-dilutive funding sources. Notably, general and administrative expenses were trimmed by ~8% quarter-over-quarter in Q3 2025 ([7]), reflecting cost discipline. With Phase 1 trials completed and Phase 2 planning underway, the company appears to have over a year’s runway to advance its pipeline before new funding is required – a relatively comfortable cushion for a pre-revenue biotech.
Step 1 — Gold: Why This Is Different
Step 2 — Silver: The Paper Squeeze
Step 3 — Uranium: Powering America's Comeback
Digital Assets as Reserves: A unique aspect of Quantum’s treasury is its investment in cryptocurrency. The company holds a portion of its cash in digital assets (primarily Bitcoin), viewing it as a diversification strategy ([7]). By Q3 2025, Quantum’s digital asset portfolio had grown to US$5.2 million, up from just $0.8 million at 2024 year-end ([7]). Year-to-date realized gains of $572k were recorded from crypto trading in 2025 ([7]), providing a modest boost to income. These crypto holdings augment liquidity – they can potentially be liquidated to fund operations – but they also introduce volatility and risk. A sharp downturn in cryptocurrency markets could erode part of Quantum’s capital base. Management believes this strategy helps manage treasury risk through diversification ([7]), but it is an unusual approach for a biotech. Aside from crypto, Quantum could see additional non-dilutive cash inflows from its legacy assets: for instance, its spun-off affiliate Unbuzzd Wellness is raising up to $5 million via a private placement, which could indirectly benefit Quantum’s 19.86% stake or royalty arrangements ([7]) ([7]). In summary, the company’s liquidity coverage of near-term needs appears strong, with traditional cash plus unconventional reserves (crypto, affiliate stakes) expected to sustain operations through planned milestones.
Coverage Ratios: Given Quantum’s negligible debt, interest coverage is not a concern – interest expense is minimal, and operating losses (while ongoing) are financed by equity capital rather than borrowing. Likewise, since no dividends are paid, dividend coverage is not applicable. The more pertinent metric is cash coverage of R&D and overhead costs. By management’s guidance, existing capital should cover over 2 years of spending at the current burn rate ([7]) ([7]). This suggests that unless the company dramatically accelerates trial spending (e.g. launching multiple Phase 2 programs in parallel), it can advance its lead candidate without near-term liquidity strain. However, investors should monitor R&D outlays as Phase 2 trials for MS and other programs ramp up – successful execution will eventually require either partnering or additional funds beyond 2027.
Valuation
Market Cap vs. Book Value: QNTM’s stock currently trades at a market capitalization of roughly US$30–32 million ([9]). This valuation far exceeds the company’s tangible book value (shareholders’ equity was ~US$7.5 million as of Q3 2025 ([7])). In other words, the stock trades at about 4× book – a premium that reflects investor expectations for Quantum’s drug pipeline rather than its current assets. Such a multiple is typical for development-stage biotech companies, where most of the firm’s value hinges on the potential future cash flows from successful drugs. With no positive earnings or cash flow (FFO/AFFO) yet, conventional valuation metrics like P/E or P/FCF are not meaningful for QNTM. Instead, the market is pricing in the risk-adjusted net present value of Quantum’s R&D programs and any intangible assets.
Pipeline-Implied Value: The majority of Quantum’s value is attributable to Lucid-MS, its lead neurological drug candidate. The successful completion of Phase 1 and toxicology studies de-risked Lucid-MS’s safety profile ([1]), but proof of efficacy in MS patients remains the key to unlocking value. If Lucid-MS ultimately proves effective in remyelinating nerves in MS, the upside could be significant given the large MS market (2.8 million patients worldwide ([2])) and the lack of curative therapies. However, this outcome is uncertain, and the current ~$30 million market cap likely reflects a relatively low probability of ultimate approval (typical for a drug only just entering Phase 2). For context, even a 10% chance of reaching a $1 billion annual sales potential could justify the current valuation – highlighting the speculative, binary nature of biotech valuation.
Comparable Metrics: In absence of earnings, investors also gauge QNTM’s valuation via enterprise value (EV) to R&D assets or relative to peers at similar stages. Quantum’s enterprise value (market cap minus net cash) is modest – roughly $25 million if we subtract its cash & crypto holdings. This EV encompasses not only Lucid-MS, but also the company’s secondary assets (e.g. the FSD-PEA anti-inflammatory program and its minority interest in Unbuzzd). By comparison, early-stage biotech peers with one or two Phase 1/2 candidates often trade in the $20–50 million EV range, depending on data strength. Quantum appears to be in the middle of that range, suggesting the market is cautiously valuing the pipeline. It’s worth noting QNTM’s stock underwent a 65:1 reverse split in 2024 ([10]) to maintain Nasdaq listing compliance, underscoring that the absolute share price (recently ~$9) is less informative than market cap. Going forward, major valuation inflection points will include Phase 2 trial initiation (or partnership announcements) and, later, any efficacy readouts for Lucid-MS. Until data emerges, QNTM’s valuation will remain speculative, balancing its cash runway and pipeline promise against the significant clinical and execution risks.
Risks
Investing in Quantum BioPharma entails substantial biotechnology risks as well as some unique company-specific risks:
– Clinical Development Risk: Lucid-MS must demonstrate in human trials that it can actually improve MS outcomes (e.g. repair myelin and restore function). All prior results are from animal models or healthy volunteer safety studies ([2]) ([2]). There is no guarantee these findings will translate into efficacy in MS patients. Failure in Phase 2 (lack of efficacy or unforeseen safety issues) would greatly impair Quantum’s lead asset value. The company’s other drug efforts (e.g. the FSD-PEA anti-inflammatory for rare mast cell disorders) are earlier-stage and were even halted and restarted, indicating uncertainty in their prospects ([3]) ([3]). In short, pipeline failure is the top risk – Quantum is essentially a one-product (Lucid-MS) company at this point.
– Regulatory and Trial Risk: The pathway to approval is long and uncertain. Quantum still needs to file an IND and get FDA clearance to start U.S. trials for Lucid-MS ([1]). Clinical trials, especially in MS, are complex and can face delays or stringent endpoints. Any hiccup in trial execution – slow enrollment, regulatory holds, or data variability – could delay development. Even if Phase 2 shows some efficacy, Phase 3 trials in MS would be large, expensive, and years-long. The FDA and other regulators will scrutinize the drug’s benefit-risk profile thoroughly ([3]). A competing MS therapy approval or changes in regulatory standards for neuro drugs could also raise the bar.
– Funding & Dilution Risk: While Quantum has no debt and a decent cash runway now, it will likely need significant additional capital to fund Phase 2 and Phase 3 trials if it proceeds alone. Biotech trials for chronic diseases like MS can cost tens of millions. The company has an ATM facility and has historically issued equity to raise cash ([8]). Any future equity offerings (or warrant exercises) could dilute existing shareholders – a familiar pattern in Quantum’s history (the share count has grown substantially since 2018, and control shareholders just approved issuing more Class A shares to themselves to facilitate future funding) ([11]) ([11]). If market conditions worsen or the stock price falls significantly, Quantum might struggle to raise capital on favorable terms ([3]) ([3]). Ensuring adequate funding without crippling dilution is an ongoing challenge.
– Competitive & Market Risk: The MS treatment landscape is competitive with many approved drugs (immunomodulators, monoclonal antibodies, etc.) and numerous clinical candidates. Even though Lucid-MS aims to be disease-modifying via remyelination (a differentiator), by the time it could reach market it may face competition from larger companies or new technologies. Achieving physician and patient adoption would require clear evidence of superior outcomes ([3]). Additionally, pricing and reimbursement for a new MS therapy can be challenging – payors will demand strong proof of benefit. If Lucid-MS only shows incremental improvement or works in a subset of patients, market acceptance risk comes into play. Quantum’s ability to eventually commercialize (likely via a partner or acquisition) is not assured.
– Key Personnel and Execution: As a small company, Quantum relies heavily on a few key individuals – executive leadership and scientists. The company’s founder/CEO Zeeshan Saeed and EVP of Scientific Affairs Dr. Andrzej Chruscinski are instrumental in both corporate strategy and drug development efforts ([1]). Loss of any key person or an inability to attract specialized talent for clinical development could hinder progress ([3]). Moreover, Quantum has multiple initiatives (CNS drugs, crypto investments, spin-off management), and management bandwidth could be stretched. Execution missteps – whether in trial management, manufacturing the new oral formulation of Lucid-MS, or handling the various business lines – pose a risk in the coming years.
– Legal and External Risks: Quantum is involved in unusual legal endeavors that carry uncertainty. The company’s high-profile lawsuit against major Canadian banks (for alleged share price manipulation) is a complex, multi-year process with unpredictable outcomes. Quantum is counting on litigation success to deliver value via CVRs, but there is a risk the case yields no meaningful reward (courts could dismiss claims or award far less than sought). Likewise, Quantum has engaged in whistleblower actions and “market integrity” campaigns ([1]) – while potentially worthwhile, these do not guarantee any payout and could divert management focus. On the external front, macroeconomic factors like tightening capital markets, inflation, or regulatory changes for crypto could hurt Quantum’s operations ([3]). For instance, a crypto market crash would directly hit its treasury holdings, and new crypto regulations (e.g. MiCA in the EU) could affect how Quantum manages those assets ([3]). Overall, investors face a broad spectrum of risks – from typical biotech clinical risk to idiosyncratic risks like legal battles and cryptocurrency exposure – which makes QNTM a high-risk, high-reward profile.
Red Flags and Governance Concerns
In addition to the risks above, several red flags stand out in Quantum BioPharma’s profile that warrant investor caution:
– Dual-Class Share Structure: Quantum has a multi-class share setup that heavily favors insiders. The founders and executives hold Class A multiple-voting shares carrying 276,660 votes each, while public investors hold Class B subordinate-voting shares (1 vote each) ([11]). Originally, this gave insiders over 75% of voting power, though dilution had reduced that to ~46% by 2025 ([11]). In October 2025, the board approved issuances of new Class A shares (sold only to the CEO and Co-Chair) to boost insider voting power back above 75% ([11]). This effectively entrenches control in the hands of CEO Zeeshan Saeed and Co-Chair Anthony Durkacz, who subscribed to these special shares ([11]) ([11]). Such a structure is a governance red flag – it means minority shareholders have little say in corporate matters and management can pass measures beneficial to themselves with minimal oversight. The recent move to restore insider voting dominance, by issuing 30 Class A shares for just $750 total ([11]) ([11]), underscores the governance risk: it was essentially an insider transaction overriding the dilutive impact of past financings. Investors should be aware that their interests may be subordinate to those of management under this structure.
– History of Dilution and Reverse Splits: Quantum (as FSD Pharma) has a track record of heavy dilution. The company raised capital frequently by issuing shares and warrants, which drove the outstanding share count up and the stock price down (necessitating a 65-for-1 reverse stock split in August 2024) ([10]). This reverse split temporarily boosted the per-share price, but also highlights how much value early shareholders lost through dilution. Furthermore, in September–November 2024 Quantum settled over $0.9 million of debts by issuing shares (and even had a creditor’s debt paid off by a third party) ([3]) ([3]), indicating reliance on equity swaps to clear liabilities. While reducing debt is positive, constantly issuing stock below market value or in private deals can erode shareholder value. The presence of an ongoing ATM equity program ([8]) means new shares could hit the market opportunistically. Prospective investors should examine how past capital raises impacted share count and be prepared for further dilution if the company funds Phase 2/3 internally.
– Related-Party Transactions: Some of Quantum’s capital allocation decisions raise eyebrows. Most notably, the company’s subsidiary FSD Strategic Investments provided a C$1.2 million secured loan to CEO Saeed in 2023, using corporate funds to finance a mortgage on the CEO’s personal real estate ([3]). While this loan earned interest and was fully repaid in 2025 ([3]) ([3]), it’s an unusual practice that blurs the line between corporate treasury management and insider benefit. The company justified it as a way to earn a return on idle cash ([3]), but such insider lending could be viewed as a conflict of interest or at least poor optics in terms of governance. Additionally, the spinoff of Unbuzzd Wellness (originally Celly Nu) involved Quantum’s management taking key roles and the company extending loans and licenses to that entity ([3]) ([3]). While potentially value-generating, these intertwining relationships require robust oversight to ensure public shareholders’ interests are protected. Any perception of self-dealing or insider enrichment at the expense of shareholders would be a red flag.
– Strategic Focus and Consistency: Quantum’s strategy at times appears scattershot, which may concern investors who prefer a clear focus. The company’s assets range from a neurological drug (Lucid-MS), to a relaunched anti-inflammatory platform (FSD-PEA) ([3]) ([3]), to a nutraceutical for alcohol detox (Unbuzzd), and even to cryptocurrency investments. Such diversity is atypical for a small biotech. In 2023, management actually halted the FSD-PEA drug program after determining it wouldn’t be profitable, only to resurrect it in 2024 to pursue a niche indication ([3]) ([3]). This kind of pivot can be seen as a red flag around strategic decision-making. The crypto treasury strategy, too, while profitable in 2025, could be viewed as a distraction from the core biotech mission. It introduces unnecessary financial risk and complexity (e.g. needing policies for safeguarding digital assets) that many biotech investors may not be comfortable with. The breadth of initiatives suggests management is trying multiple avenues for value, but it also raises the question of whether they are truly focused on executing the critical path (Lucid-MS clinical trials). Investors should watch for continued discipline – e.g. avoiding new unrelated ventures or excessive diversification – to ensure Quantum’s resources stay concentrated on its best opportunities.
– Frequent Legal and Promotional Actions: Another potential red flag is Quantum’s engagement in legal fights and promotional campaigns. The company has pursued litigation not only against alleged stock manipulators, but also was involved in a class-action lawsuit (now settled) over past management actions ([12]), and it regularly issues updates about market integrity and whistleblower efforts ([1]). While fighting for shareholder value is commendable, it suggests an environment of controversy and contention. Similarly, Quantum has enlisted investor relations firms and media strategies to boost its profile ([3]). Aggressive promotion can sometimes indicate that a micro-cap stock’s story is being actively “sold” to the public, which savvy investors take with caution. None of these flags are deal-breakers on their own, but collectively they paint a picture of a company that is unconventional and potentially higher-risk on governance. Robust due diligence is warranted.
Open Questions & Outlook
As Quantum BioPharma moves past its latest milestone and looks ahead, several open questions remain:
– When and How Will Phase 2 Commence? Now that 180-day toxicity studies are done, the next step is filing an IND and launching a Phase 2 trial for Lucid-MS ([1]). An open question is timeline – will Phase 2 begin in 2026, and if so, when might initial efficacy data arrive? The company has also been developing an oral formulation of Lucid-MS (capsule form) for the upcoming trial ([13]). It remains to be seen if this oral version will perform as well as the injectable form did in preclinical tests. Clarity on trial design (dose, patient population, endpoints) will be important in gauging the drug’s chances. Additionally, partnership potential hovers: will Quantum seek a pharma partner before Phase 2 (to help fund it) or attempt Phase 2 on its own and look for partners after proof-of-concept? The strategy management chooses will influence the risk/reward for shareholders.
– Can Quantum Remain Focused on MS? With multiple projects in its portfolio, an open question is whether Quantum will concentrate its efforts or continue a multi-pronged approach. The FSD-PEA program was restarted for a Phase 2 trial in a rare disorder (mast cell activation syndrome) ([3]). Will this program progress meaningfully, or could it divert attention and cash from Lucid-MS? Similarly, Quantum retains rights to Lucid-PSYCH, a potential mental-health candidate that is currently on hold ([3]) ([3]). Investors are left wondering if/when that asset might be revisited. The core value driver is clearly Lucid-MS; how management balances other pipeline opportunities without losing focus on the flagship program is an open question.
– What is the Endgame for Unbuzzd and Other Non-Core Assets? Quantum’s roughly 20% stake in Unbuzzd Wellness (the company commercializing the “unbuzzd” alcohol detox supplement) could become either a valuable asset or a distraction. Unbuzzd recently obtained a Canadian product license and is raising money for a potential public listing ([7]). How and when Quantum will monetize or benefit from this stake is unclear. Will Unbuzzd’s planned $5 million financing (via Reg D offering) provide any near-term cash back to Quantum ([7])? And if Unbuzzd goes public, will Quantum distribute or sell its remaining stake? A successful launch of the Unbuzzd product could mean royalty streams and equity appreciation for Quantum ([1]), but the timeline and magnitude are uncertain. Likewise, Quantum’s cryptocurrency holdings pose the question: will the company continue to allocate treasury funds to crypto in 2026 and beyond, or was 2025’s foray a one-time opportunistic move? The answer may depend on market conditions; however, investors will want to see that core R&D isn’t starved for funds due to non-core investments.
– Outcome of the Legal Battle: A big wildcard is the pending litigation against financial institutions. Quantum’s management appears confident given they set up a CVR for shareholders, but lawsuits of this nature can take years and may never result in a win. An open question is whether the company might settle the case (and for how much), or if it will pursue it fully through courts. If a substantial settlement or judgment materializes, it could inject significant cash into Quantum (of which 50% max would pass to CVR holders) ([5]). On the other hand, if the case is dismissed or quietly dropped, Quantum will have expended effort (and perhaps legal fees) for no return. Investors should not base the valuation on this speculative outcome, but it remains an upside wildcard. Clarity on the next steps or any progress in 2026 would help gauge if this is a real asset or a long-shot endeavor.
– Will Governance Improve or Worsen? Finally, from a governance perspective, one wonders if Quantum will take steps to address investor concerns or if insider control will tighten further. For example, will the company eventually sunset the dual-class share structure or at least refrain from actions that dilute minority voting power? The alignment of management’s incentives with ordinary shareholders is a question – with insiders so firmly in control, outside investors must trust they will act in all shareholders’ interests. Any moves like hiring independent directors, improving transparency, or focusing strategy could help build investor confidence. Conversely, additional related-party deals or promotional hype without execution would be negative signals.
In conclusion, Quantum BioPharma has reached a critical juncture with its Lucid-MS program entering the Phase 2 realm. The achievement of a key preclinical milestone ([1]) underscores the promise of its science, while a cleaned-up balance sheet and ample runway provide a foundation for the next steps ([7]) ([7]). However, QNTM remains a high-risk, early-stage investment. The company’s fortunes hinge on clinical success in MS and prudent management of resources. Investors should keep a close watch on upcoming catalysts – IND filings, trial initiations, funding updates, and any pipeline news – and weigh them against the backdrop of Quantum’s unconventional corporate maneuvers. A major breakthrough in efficacy could unlock substantial upside, but until then Quantum BioPharma will need to navigate its risks and prove that it can translate innovative ideas (like Lucid-MS’s remyelination approach) into tangible results for patients and shareholders alike.
Sources: Quantum BioPharma SEC filings, press releases, and investor communications ([3]) ([1]) ([7]) ([11]), supplemented by reputable financial media and market data ([9]) ([7]). All information is current as of December 24, 2025.
Sources
- https://quiverquant.com/news/Quantum%2BBioPharma%2BCompletes%2BOral%2BDosing%2Bof%2BLucid-MS%2Bin%2B180-Day%2BToxicity%2BStudies%2C%2BAdvancing%2BPhase%2B2%2BTrial%2BPlans%2Bfor%2BMultiple%2BSclerosis
- https://quantumbiopharma.com/lucid-ms
- https://fintel.io/doc/sec-quantum-biopharma-ltd-1771885-20f-2025-march-28-20175-3344
- https://stockevents.app/en/stock/QNTM/dividends
- https://globenewswire.com/news-release/2025/6/13/3098927/0/en/Quantum-BioPharma-Announces-Intention-to-Declare-Special-Dividend-of-Contingent-Value-Rights-CVRs-Linked-to-Future-Litigation-Settlement-Proceeds.html
- https://globenewswire.com/news-release/2025/10/20/3169362/0/en/Quantum-BioPharma-Ltd-Announces-Expiration-of-All-Warrants-Held-by-Hedge-Funds-and-Re-Iterates-October-27-2025-Record-Date-for-the-Distribution-of-a-Special-Dividend.html
- https://marketchameleon.com/PressReleases/i/2201723/QNTM/quantum-biopharma-reports-strong-third-quarter-results
- https://sec.gov/Archives/edgar/data/1771885/000117184325006869/exh_991.htm
- https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qntm/quantum-biopharma
- https://stocktitan.net/news/HUGE/fsd-pharma-completes-name-change-to-quantum-bio-pharma-and-65-1-08zbqbjsde4w.html
- https://nasdaq.com/press-release/quantum-biopharma-ltd-announces-corporate-updates-2025-10-29
- https://sa.marketscreener.com/quote/stock/QUANTUM-BIOPHARMA-LTD-43536373/news/FSD-Pharma-Announces-Settlement-of-Class-Action-Proceeding-31647214/
- https://stocktitan.net/news/QNTM/quantum-bio-pharma-signs-agreement-to-manufacture-oral-drug-9segd9rip6hg.html
For informational purposes only; not investment advice.